THERAPEUTIC REVOLUTION The History of Medical Oncology from Early Days to the Creation of the Subspecialty

Indexed in: EBSCO.

Cancer is a disease responsible for several million annual deaths among humans, worldwide. However, advances in healthcare - which include breakthroughs in science and medicine as well as access to ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Breast Cancer: 2. A Paradigm for Solid Tumor Chemotherapy

Pp. 130-145 (16)

Pierre R. Band

Abstract

In the early 1960s, breast cancer was considered to be poorly responsive to chemotherapy. However, several agents, in particular methotrexate, vincristine, 5- fluorouracil, cyclophosphamide, an alkylating agent synthesized in Germany, and prednisone were found to be active in women with metastatic breast cancer. These five drugs were then used in advanced breast cancer in a combination referred to as the “Cooper regimen” that triggered a number of studies using quadruple and quintuple chemotherapeutic drug combinations which induced response rates superior to therapy with single agents. These results led to the integration of combination chemotherapy into a combined modality approach, epitomized by modern ʻadjuvantʼ chemotherapy. A first randomized study comparing long-term postoperative single drug chemotherapy to a placebo led to improved survival in a subset of patients. Superior results were subsequently achieved with postoperative combination chemotherapy. The historical development of these approaches is described.

Keywords:

Breast cancer, single agent chemotherapy, combination chemotherapy, postoperative (ʻadjuvantʼ) chemotherapy.

Affiliation:

Faculty of Medicine, McGill University, Montreal, Quebec H3G 1Y6, Canada.